268 related articles for article (PubMed ID: 26453583)
41. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
42. Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation.
Sakimoto T; Ishimori A
Exp Eye Res; 2016 Apr; 145():110-117. PubMed ID: 26689752
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
[TBL] [Abstract][Full Text] [Related]
44. Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease.
Cauwe B; Martens E; Sagaert X; Dillen C; Geurts N; Li S; Mertens J; Thijs G; Van den Steen PE; Heremans H; De Vos R; Blockmans D; Arnold B; Opdenakker G
J Autoimmun; 2011 May; 36(3-4):239-52. PubMed ID: 21376533
[TBL] [Abstract][Full Text] [Related]
45. Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse.
Zhou T; Bluethmann H; Eldridge J; Berry K; Mountz JD
J Immunol; 1993 Apr; 150(8 Pt 1):3651-67. PubMed ID: 7682246
[TBL] [Abstract][Full Text] [Related]
46. Investigation of common variable immunodeficiency patients and healthy individuals using autoimmune lymphoproliferative syndrome biomarkers.
Roberts CA; Ayers L; Bateman EA; Sadler R; Magerus-Chatinet A; Rieux-Laucat F; Misbah SA; Ferry BL
Hum Immunol; 2013 Dec; 74(12):1531-5. PubMed ID: 23993982
[TBL] [Abstract][Full Text] [Related]
47. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
48. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
[TBL] [Abstract][Full Text] [Related]
49. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W
Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790
[TBL] [Abstract][Full Text] [Related]
50. Hypogammaglobulinaemia occurs in Fas-deficient MRL-lpr mice following deletion of MHC class II molecules.
Anderson CC; Mukherjee R; Sinclair NR; Jevnikar AM
Clin Exp Immunol; 1997 Sep; 109(3):473-9. PubMed ID: 9328125
[TBL] [Abstract][Full Text] [Related]
51. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
52. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Huang F; Luo ZC
Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
[TBL] [Abstract][Full Text] [Related]
53. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
54. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
55. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas(lpr) mice.
Feeney AJ; Lawson BR; Kono DH; Theofilopoulos AN
J Immunol; 2001 Sep; 167(6):3486-93. PubMed ID: 11544342
[TBL] [Abstract][Full Text] [Related]
56. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.
Consonni F; Gambineri E; Favre C
Ann Hematol; 2022 Mar; 101(3):469-484. PubMed ID: 35059842
[TBL] [Abstract][Full Text] [Related]
57. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Clowse ME; Feldman SR; Isaacs JD; Kimball AB; Strand V; Warren RB; Xibillé D; Chen Y; Frazier D; Geier J; Proulx J; Marren A
Drug Saf; 2016 Aug; 39(8):755-62. PubMed ID: 27282428
[TBL] [Abstract][Full Text] [Related]
58. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).
Teachey DT; Seif AE; Grupp SA
Br J Haematol; 2010 Jan; 148(2):205-16. PubMed ID: 19930184
[TBL] [Abstract][Full Text] [Related]
59. Response of alopecia areata of the beard to oral tofacitinib.
Kerkemeyer KLS; John JM; Sinclair R; Bhoyrul B
J Am Acad Dermatol; 2020 May; 82(5):1228-1230. PubMed ID: 31678329
[No Abstract] [Full Text] [Related]
60. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
Ann Intern Med; 2013 Aug; 159(4):I-26. PubMed ID: 24026272
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
